Oseltamivir is a specific neuraminidase inhibitor, which can inhibit the mature influenza virus from leaving the host cell, thus inhibiting the spread of influenza virus in human body and playing a role in treating influenza. Oseltamivir is a successful case of rational drug design based on structure. Computer-aided drug design has been widely used in the research and development of this drug. According to the three-dimensional structure of the target enzyme, a neuraminidase inhibitor with high efficiency, low toxicity and strong specificity was designed.
Roche Pharmaceutical Co., Ltd. is the patent holder of oseltamivir, and its oseltamivir phosphate capsules (Tamiflu in Chinese mainland, Tamiflu in Hongkong and Influenza in Taiwan Province Province) are the only oseltamivir preparations on the market at present. From June 5438 to October 2005 10, due to the global spread of avian influenza, there was a global rush to buy Tamiflu, and Roche was widely condemned for refusing to open the patent right of oseltamivir and restricting the sale of Tamiflu.